Immtech Home page Immtech company Immtech Business Development Immtech contact Immtech Technology Immtech R&D pipeline
Immtech Investor Information Immtech Business Model Immtech investor news releases Immtech SEC Filings Immtech Corporate Governance Immtech FAQs  


Press Releases
(cont)

12 June 2007
Immtech And PAR Enter Licensing Agreement On Parfurmidine For Treatment Of Pneumocystis Pneumonia In The U.S.

09 April 2007
Immtech Initiates Phase IIb Clinical Trial to Develop Malaria Prevention and Treatment Therapies

09 February 2007
Immtech Reports Fiscal Third Quarter 2007 Results

07 February 2007
Immtech Announces Registered Offering of One Million Shares in Common Stock

30 January 2007
Immtech Completes Enrollment in Phase III Pivotal Trial of Pafuramidine for African Sleeping Sickness

24 January 2007
Patent Issued For Compounds With Potential To Treat BVDV And HCV

09 December 2006
Immtech Initiates Phase II of Pafuramidine Maleate (DB289) as a Prophylaxis for the Prevention of Malaria

21 November 2006
US FDA Grants Immtech's Oral Drug Candidate Pafuramidine (DB289) Orphan Drug Status for Treatment of PCP

10 November 2006
Immtech Investor Conference Call Scheduled For Tuesday, November 21, 2006

9 November 2006
Immtech Reports Fiscal Second Quarter 2007 Results

07 November 2006
Immtech Pharmaceuticals to Present at the BIO-Europe 2006 Conference

02 November 2006
Immtech Pharmaceuticals Among Fastest Growing Companies Named by Deloitte

25 October 2006
Immtech Adds New Board Member

12 October 2006
Immtech Pharmaceuticals Announces Antimicrobial Pipeline Progress

19 September 2006
Immtech Scientific Collaborators Receive $21.3 Million Bill and Melinda Gates Foundation Grant

23 August 2006
Immtech Taps Harvard Scientist And International Policy Expert Dr. Dorothy Zinberg As Consulting Strategic Advisor

09 August 2006
Immtech Reports Fiscal First Quarter 2007 Results

25 July 2006
Immtech Appoints Carol Ann Olson, MD To Senior Vice President Of Pharmaceutical Development And Chief Medical Officer

21 July 2006
Immtech Investor Conference Call Scheduled For Tuesday, July 25, 2006

21 July 2006
Patent Issued For Method To Manufacture Immtech's Drug Candidate Compounds

14 June 2006
Immtech Reports Fiscal Year End 2006 Results

12 June 2006
Immtech Investor Conference Call Scheduled for Wednesday, June 14, 2006

12 June 2006
Arbitral Tribunal Finds For Immtech

23 May 2006
Immtech Receives Expanded Funding Commitment To Develop Pafuramidine Maleate(DB289) For African Sleeping Sickness

16 May 2006
Immtech Pharmaceuticals To Present At Rodman & Renshaw 3rd Annual Global Healthcare Conference

03 May 2006
Immtech Pharmaceuticals Announces Retirement of T. Stephen Thompson, President And Board Member

27 March 2006
Immtech Pharmaceuticals Initiates Phase III Pivotal Trial of Pafuramidine Maleate (DB289) to Treat Pneumocystis Pneumonia in HIV/AIDS Patients

23 March 2006
Immtech International, Inc. becomes Immtech Pharmaceuticals, Inc.

13 March 2006
Immtech Announces DB289's Name "Pafuramidine Maleate"

<<previous

Download the free Adobe Acrobat PDF reader.

 

Terms of Use | Privacy Policy
© 2008 Immtech. All Rights Reserved